Inflammaging: Implications in Sarcopenia

Int J Mol Sci. 2022 Nov 30;23(23):15039. doi: 10.3390/ijms232315039.

Abstract

In a world in which life expectancy is increasing, understanding and promoting healthy aging becomes a contemporary demand. In the elderly, a sterile, chronic and low-grade systemic inflammation known as "inflammaging" is linked with many age-associated diseases. Considering sarcopenia as a loss of strength and mass of skeletal muscle related to aging, correlations between these two terms have been proposed. Better knowledge of the immune system players in skeletal muscle would help to elucidate their implications in sarcopenia. Characterizing the activators of damage sensors and the downstream effectors explains the inference with skeletal muscle performance. Sarcopenia has also been linked to chronic diseases such as diabetes, metabolic syndrome and obesity. Implications of inflammatory signals from these diseases negatively affect skeletal muscle. Autophagic mechanisms are closely related with the inflammasome, as autophagy eliminates stress signaling sent by damage organelles, but also acts with an immunomodulatory function affecting immune cells and cytokine release. The use of melatonin, an antioxidant, ROS scavenger and immune and autophagy modulator, or senotherapeutic compounds targeting senescent cells could represent strategies to counteract inflammation. This review aims to present the many factors regulating skeletal muscle inflammaging and their major implications in order to understand the molecular mechanisms involved in sarcopenia.

Keywords: aging; inflammation; sarcopenia; skeletal muscle.

Publication types

  • Review

MeSH terms

  • Aged
  • Aging / physiology
  • Humans
  • Inflammation / pathology
  • Muscle, Skeletal / metabolism
  • Obesity / metabolism
  • Sarcopenia* / metabolism

Grants and funding

This work was supported by the following funding sources: Instituto de Salud Carlos III, grant numbers FISS-18-PII17/02009 and PI21/01596; the Government of the Principado de Asturias through the Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología (FICYT) and the European Union, GRUPIN grant number IDI/2021/000033 and AYUD/2021/9867; the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), grant number AYUD/2021/58477, grant number 2021-030-INTRAMURALES-POOCY University of Oviedo and grant number PAPI-19-EMERG-2. E.A. thanks his pre-doctoral fellowship to University of Oviedo, grant number PAPI-21-PF-28; J.C.B.-M. thanks his pre-doctoral fellowship to Instituto de Salud Carlos III, grant number FI18/00149 and C.G.-G. thanks her postdoctoral fellowship to FICYT-Ayudas Margarita Salas Joven grant number AYUD/2021/58477.